![]() |
Name |
Bionectin E
|
Molecular Formula | C24H22N4O3S2 | |
IUPAC Name* |
(1S,2S,3R,11R,14S)-14-ethyl-2-hydroxy-3-(1H-indol-3-yl)-18-methyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione
|
|
SMILES |
CC[C@]12C(=O)N3[C@@H]4[C@]([C@@H]([C@@]3(C(=O)N1C)SS2)O)(C5=CC=CC=C5N4)C6=CNC7=CC=CC=C76
|
|
InChI |
InChI=1S/C24H22N4O3S2/c1-3-22-20(30)28-19-23(14-9-5-7-11-17(14)26-19,15-12-25-16-10-6-4-8-13(15)16)18(29)24(28,33-32-22)21(31)27(22)2/h4-12,18-19,25-26,29H,3H2,1-2H3/t18-,19+,22-,23+,24-/m0/s1
|
|
InChIKey |
HURRRPHPMBYTBV-CGXVDHOPSA-N
|
|
Synonyms |
Bionectin E
|
|
CAS | NA | |
PubChem CID | 145720712 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 478.6 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 139.0 | Aromatic Rings: | 8 |
Heavy Atoms: | 33 | QED Weighted: | 0.485 |
Caco-2 Permeability: | -5.352 | MDCK Permeability: | 0.00001160 |
Pgp-inhibitor: | 0.057 | Pgp-substrate: | 0.063 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.013 |
30% Bioavailability (F30%): | 0.758 |
Blood-Brain-Barrier Penetration (BBB): | 0.339 | Plasma Protein Binding (PPB): | 87.61% |
Volume Distribution (VD): | 0.869 | Fu: | 6.99% |
CYP1A2-inhibitor: | 0.073 | CYP1A2-substrate: | 0.403 |
CYP2C19-inhibitor: | 0.968 | CYP2C19-substrate: | 0.926 |
CYP2C9-inhibitor: | 0.971 | CYP2C9-substrate: | 0.805 |
CYP2D6-inhibitor: | 0.763 | CYP2D6-substrate: | 0.124 |
CYP3A4-inhibitor: | 0.957 | CYP3A4-substrate: | 0.969 |
Clearance (CL): | 10.681 | Half-life (T1/2): | 0.066 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.184 |
Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.975 | Maximum Recommended Daily Dose: | 0.798 |
Skin Sensitization: | 0.827 | Carcinogencity: | 0.791 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.344 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002358 | ![]() |
0.810 | D0QV5T | ![]() |
0.294 | ||
ENC003530 | ![]() |
0.619 | D0V3ZA | ![]() |
0.292 | ||
ENC003382 | ![]() |
0.520 | D01TSI | ![]() |
0.292 | ||
ENC004849 | ![]() |
0.503 | D09NNH | ![]() |
0.283 | ||
ENC003176 | ![]() |
0.442 | D0E3OF | ![]() |
0.282 | ||
ENC003381 | ![]() |
0.428 | D07VHR | ![]() |
0.280 | ||
ENC003588 | ![]() |
0.425 | D0BV3J | ![]() |
0.278 | ||
ENC003490 | ![]() |
0.415 | D08FTG | ![]() |
0.277 | ||
ENC003455 | ![]() |
0.413 | D0SP3D | ![]() |
0.275 | ||
ENC002642 | ![]() |
0.402 | D02DMQ | ![]() |
0.274 |